Australian author and academic David Tuffley challenges bold claims that a neuroprosthetic device developed by Elon Musk's Neuralink start-up company could “cure tinnitus” within five years, in an article on “The Conversation” website.
Medical device company, Neuromod Devices Ltd, announced that it has launched Ótologie, a “specialist telehealth service for tinnitus.” This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
To mark Tinnitus Week (February 1-7, 2021), The British Irish Hearing Instrument Association (BIHIMA) announced the results of a survey that questioned its research panel of UK audiologists on the subject of tinnitus awareness.
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
The interface incorporates a sound therapy library which has proved to be effective tinnitus therapy, particularly for those who have trouble sleeping.